NCT01758965

Brief Summary

The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
146

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

December 27, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 1, 2013

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

May 13, 2014

Status Verified

May 1, 2014

Enrollment Period

1 year

First QC Date

December 27, 2012

Last Update Submit

May 12, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Delayed bleeding rate after ESD

    1 year

Study Arms (2)

combination therapy of H2RA and surgicel

EXPERIMENTAL

H2RA and surgicel

Other: H2RA and surgicel

Monotherapy of PPI

EXPERIMENTAL

PPI

Other: PPI

Interventions

PPIOTHER

monotherapy of PPI

Monotherapy of PPI

combination therapy of H2RA and surgicel

combination therapy of H2RA and surgicel

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ESD for gastric dysplasia or early gastric cancer

You may not qualify if:

  • Coagulopathy: liver cirrhosis, thrombocytopenia
  • Anti-platelet agents

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University College of Medicine

Bucheon-si, Gyeonggi-do, 420-767, South Korea

Location

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

Surgicel

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

December 27, 2012

First Posted

January 1, 2013

Study Start

December 1, 2012

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

May 13, 2014

Record last verified: 2014-05

Locations